Clinical trial
Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer…
NCT00030472 · Gynecologic Oncology Group, Other · Terminated
Key facts
| NCT number | NCT00030472 |
|---|---|
| Title | Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix |
| Official title | A Phase II Evaluation of Liposomal Doxorubicin (Doxil) in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Cancer |
| Intervention type | Drug |
| Interventions | pegylated liposomal doxorubicin hydrochloride |
| Start date | Dec 1, 2001 |
| Primary completion | Oct 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 11, 2013 |
| Countries | Norway, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: